Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Doxepin Articles

Somaxon secures $65M financing

2 June 2008

Ph III Silenor data confirms positive data package

19 May 2008

US FDA to update black box warnings for young adults taking antidepressants

14 May 2007

Headlines 25 years ago this week....

22 January 2007

Somaxon's Silenor effective in Ph III insomnia studies

17 April 2006

Bradley Pharma in deal with DPT Labs

24 January 2005

At least 20% of US seniors are given inappropriate scripts, new study finds

23 August 2004

Bradley closes acquisition of Bioglan

16 August 2004

Bradley to buy Bioglan in $183M deal

21 June 2004

Bioglan buys Medicis' dermatological range

6 July 1999

HHS RECOMMENDATIONS FOR ANTIDEPRESSANTS

3 May 1993

DEPRESSION: THE COST TO SOCIETY

6 April 1992

DEPRESSION: THE COST TO SOCIETY

6 April 1992

Showing 1-13 of 13 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Italy's pharma market slump set to continue, warns GlobalData
  • Is failure to adopt business process management putting the pharma industry at risk?

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS